Carreño J E, Alvarez C E, Narciso G I San, Bascarán M T, Díaz M, Bobes J
Clínica Médico Psicológica Asturias, C/Astrurias, 8 - 5a planta, 33206, Gijón, Spain.
Addict Biol. 2003 Dec;8(4):429-38. doi: 10.1080/13556210310001646402.
A report is presented of treatment of 156 patients (male 98%) with opioid dependence (ICD-10 criteria) using a maintenance programme with depot opioid antagonists (naltrexone) as subcutaneous implants, started after an outpatient rapid antagonization regimen. The retention index in the treatment was from 80% in the sixth month, and 65% after one year. The patients were followed-up for 1 year after discharge. For 6 months after discharge 55.4% were still returning for follow-up visits and 20.8% after 1 year, all of them remaining abstinent to opioids. It is concluded that the programme is safe for the patients and shows a better retention index than programmes using oral antagonists, with an improved compliance (negative urine analysis) compared to the latter.
本文报告了156例符合国际疾病分类第10版(ICD - 10)标准的阿片类药物依赖患者(男性占98%)的治疗情况。治疗采用长效阿片类拮抗剂(纳曲酮)皮下植入维持方案,该方案在门诊快速拮抗治疗方案后启动。治疗中的留存率在第6个月为80%,1年后为65%。患者出院后随访1年。出院后6个月,55.4%的患者仍返回接受随访,1年后为20.8%,所有患者均保持对阿片类药物的戒断状态。结论是该方案对患者安全,与使用口服拮抗剂的方案相比,留存率更高,且与后者相比依从性更好(尿液分析呈阴性)。